Dianthus Therapeutics 320% Year: What Investors Should Know as Stakes Shift
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
Ways To Make Additional Income
There are countless ways to make additional income. Find the best methods that suit your skills and schedule to enhance your earnings.
17,258 articlesBitget Launches Platform Reality for Tokenized Assets
Bitget unveils Reality, a new tokenization platform delivering tokenized access to select U.S. stocks and ETFs as mar...
Crypto Markets Dump $140B as Bitcoin Tumbles Toward $65K
Bitcoin led a broad retreat as the crypto market shed about $140B in value over 24 hours, pushing total capitalizatio...
More Plaintiffs Join Unison HEI Lawsuit in Colorado
A federal class-action in Colorado expands as new homeowners join the suit against Unison. Plaintiffs allege Unison's...
McGraw Hill Buys 22,000 Shares: Is This Bullish for MH Investors?
When a CEO steps up with a sizable open-market purchase, investors take note. We unpack what McGraw Hill's 22,000-sha...
Oracle Could Be a Trillion-Dollar Company by 2030: Advances
Oracle reports a powerful cloud quarter and record backlog, signaling a potential future milestone. Yet mounting capi...
ZachXBT Sounds Alarm Over AscendEX Liquidity Crisis
AscendEX ceased normal operations on July 1 as MiCA rules tightened, with withdrawal requests slowed or blocked. Zach...
Shares Spacemobile Collapsed This Week: What Investors Know
AST SpaceMobile faced a sharp weekly drop after announcing a large convertible debt raise. This article explains why ...
Down 22%, Should CrowdStrike Stock Be Bought on the Dip?
CrowdStrike has pulled back from recent highs. Before March 3 earnings, investors wonder if a dip offers a real buyin...
Acadia (Acad) 2025 Earnings: A Detailed Investor Look
A clear, reader-friendly breakdown of Acadia’s Q4 2025 earnings. We unpack revenue trends, pipeline progress, and key...
Canaccord Slashes AeroVironment Target Yet Keeps Buy Rating
Canaccord Genuity lowers AeroVironment's target to $330 but preserves a Buy rating, underscoring long-term optimism a...
Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status